Yana Feodorova1, Dessislava Tashkova2, Kiril Simitchiev3, Anton Todorov4, Gancho Kostov5, Rossen Dimov5, Victoria Sarafian1
1) Department of Medical Biology, Medical University-Plovdiv, Bulgaria;
2) Department of General and Clinical Pathology, Medical University-Plovdiv, Bulgaria;
3) Department of Analytical Chemistry and Computer Chemistry, University of Plovdiv “Paisii Hilendarski”, Bulgaria;
4) Department of Propedeutics of Surgical Diseases, Medical University-Plovdiv, Bulgaria;
5) Department of Medical Biology, Medical University-Plovdiv, Bulgaria.
Disclosure: The author has declared no conflicts of interest.
Received: 09.07.15 Accepted: 23.07.15
Colorectal cancer (CRC) is one of the most deadly cancers worldwide. Despite the introduction of targeted molecular therapies in the last 10 years, overall survival has not increased substantially. CRC progression is accompanied by numerous genetic and epigenetic alterations and dysregulation of several signaling pathways, among which activation of Wnt and inactivation of TGF-β signaling. The molecular heterogeneity of CRC, however, hinders the molecular subtyping of CRC and thus the identification of common biomarkers for this pathology. The only three well established biomarkers for advanced-colorectal-cancer drug treatment are negative biomarkers. These are mutations in the genes KRAS, NRAS and BRAF which determine resistance to therapy with anti-EGFR antibodies. YKL-40 is a chitin-binding glycoprotein that has been shown to play a role in extracellular tissue remodeling, angiogenesis, cell migration and inflammation. Increased serum levels of this protein have been detected in patients with CRC but the role of YKL-40 in this neoplastic disease has not been studied extensively and the precise function of YKL-40 in CRC progression is not known. In the present study we determined the KRAS mutation status and measured the mRNA levels of YKL-40 of 24 patients with sporadic CRC. In addition, we assessed the association between these two parameters by statistical analysis. We are the first to show that in CRC YKL-40 mRNA levels are dependent on the presence of KRAS mutations, being prominently elevated in the wild type background. Our results indicate the potential role of YKL-40 as a target molecule for CRC therapy.
Keywords: colorectal cancer (CRC), YKL-40 gene expression, KRAS mutations, target therapy.
How to Cite this Article
Citations, Quotes & Annotations
- WATCH AND WAIT APPROACH IN RECTAL CANCER TREATMENT
- TREATMENT OF RENAL STONES WITH PERCUTANEOUS NEPHROLITHOTOMY IMPROVES RENAL FUNCTIONS IN CHRONIC KIDNEY DISEASE PATIENTS
- CLINICOPATHOLOGICAL FACTORS ASSOCIATED WITH POSITIVE PREOPERATIVE AXILLARY ULTRASOUND SCANNING IN BREAST CANCER PATIENTS
- THE EFFECT OF HYDROGEN PEROXIDE ON THE HEALING OF THE LAID OPEN WOUND IN THE TREATMENT OF CHRONIC SACROCOCCYGEAL PILONIDAL SINUS: A RETROSPECTIVE DATABASE ANALYSIS OF 500 PATIENTS
- MULTIVISCERAL RESECTION FOR COLORECTAL CANCERS: AN ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOMES